Vetter works towards a sustainable energy supply
The Center for Visual Inspection and Logistics in Ravensburg which recently was awarded as a Facility of the Future, applies modern workflows and a sustainable energy concept. (Source: Vetter Pharma International GmbH.)
All German sites of the pharmaceutical service provider will be supplied with green electricity.
Vetter has reached another important milestone regarding sustainability. Beginning immediately, all German sites of the company will be supplied with only CO2 neutral energy from certified renewable energy sources.
As a partner of biotechnology and pharmaceutical customers both large and small, Vetter has been meeting high international sustainability requirements for many years. The company is certified according to the standards for environmental protection ISO 14001, energy management ISO 50001, as well as occupational health and safety BS OHSAS 18001.
“Sustainability is a central pillar of Vetter’s corporate philosophy and our stance on this subject is firmly anchored within our organization. The supply of our German sites with green electricity is an important part of our company-wide program for environmental protection, energy management, and occupational health and safety,” explains Managing Director Thomas Otto. “Our aim is to act holistically and develop our multi-faceted initiatives in these areas on a continuous basis.”
The next milestone has already been set. Within the next 10 years, Vetter plans to offset the company-wide use of natural gas, making it completely CO2 neutral. Unavoidable CO2 emissions are offset by investments in high-quality climate protection projects.
The largest sustainability project the CDMO recently implemented is at its state-of-the-art center for visual inspection and logistics, which received the international industry prize Facility of the Year Award (FOYA) in 2018 as a Facility of the Future. The site consequently realizes a sustainable energy concept specifically developed by Vetter. This includes the operation of a modern, environmentally friendly block heating and power plant, the use of geothermal energy and the comprehensive use of excess energy, as well as powerful photovoltaic systems, all of which are combined in an energy-efficient manner.
The company-wide EHS program also includes actions for sustainable, resource-efficient management, the promotion of healthy working conditions, and regular training for all staff members to raise their individual awareness of responsible behaviour.
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.